- Jan 18, 2001
- 3,445
- 1,144
- 113
- School/Org
- ODwire
- City
- Lansdale
- State
- PA
DALLAS, August 21, 2025—Diffusion Optics Technology™ (DOT™) spectacle lenses have been worn by one million children to control their myopia—a major milestone that reflects the critical need for myopia control solutions and the strong performance and trust in DOT™ lenses’ unique design.*
DOT™ lenses, developed by SightGlass Vision, first became available in 2021 and have since gained significant momentum. With launches across Asia-Pacific, Europe, and North America, over 500,000 children are estimated to have been fitted with DOT™ lenses in 2025 alone, based on global sales data.
The design of DOT™ lenses is underpinned by contrast management. High artificial contrast levels in the modern visual environment may be linked to accelerated eye growth that results in the progression of myopia.[1] DOT™ lenses mimic more natural contrast environments by incorporating thousands of elements that gently scatter light before it reaches the retina.[2]
Clinical studies have demonstrated that DOT™ lenses can slow average myopia progression by up to 75% after 12 months of wear across diverse populations.[2],[3],‡ The lenses are more than just effective, in fact 93% of children said they love their glasses with DOT™ lenses.[4],[5],‡
“Reaching one million children is a powerful testament to what our clinical studies have already shown—DOT™ lenses work, eye care professionals trust them, and children want to wear them,” said Andrew Sedgwick, CEO of SightGlass Vision. “It’s encouraging to see eye care professionals increasingly embrace this innovation for their young patients, marking another meaningful step towards combatting the global myopia epidemic. We remain committed to bringing DOT™ lenses to children in more parts of the world.”
SightGlass Vision’s patent-protected technology has made its commercial debut in several markets, including China, the Netherlands, Israel, Canada, and Spain, as well as through preliminary market trials in other countries. † Founded in 2016, SightGlass Vision is a joint venture of CooperCompanies and EssilorLuxottica. For more information, visit SightGlassVision.com.
About SightGlass Vision
SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology
is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.
*This figure is based on sales data and reflects global usage across multiple regions.
†SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.
‡Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Lenses were worn 10 hours per day.
[1] Biswas S, El Kareh A, Qureshi M, Lee DMX, Sun CH, Lam JSH, Saw SM, Najjar RP. The influence of the environment and lifestyle on myopia. J Physiol Anthropol 2024;43(1):7.
[2] Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol 2023;107:1709-1715.
[3] Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2815.
[4] McParland et al. Children adapt well to Diffusion Optics Technology™ (DOT) spectacle lenses . Presented at NCC 2024.
After 2–3 days of wearing the allocated spectacle lenses, the rate of adaptation was the same for DOT™ lenses and SV lenses (97% overall in each group).
[5] SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n=256, 14 North American sites).
DOT™ lenses, developed by SightGlass Vision, first became available in 2021 and have since gained significant momentum. With launches across Asia-Pacific, Europe, and North America, over 500,000 children are estimated to have been fitted with DOT™ lenses in 2025 alone, based on global sales data.
The design of DOT™ lenses is underpinned by contrast management. High artificial contrast levels in the modern visual environment may be linked to accelerated eye growth that results in the progression of myopia.[1] DOT™ lenses mimic more natural contrast environments by incorporating thousands of elements that gently scatter light before it reaches the retina.[2]
Clinical studies have demonstrated that DOT™ lenses can slow average myopia progression by up to 75% after 12 months of wear across diverse populations.[2],[3],‡ The lenses are more than just effective, in fact 93% of children said they love their glasses with DOT™ lenses.[4],[5],‡
“Reaching one million children is a powerful testament to what our clinical studies have already shown—DOT™ lenses work, eye care professionals trust them, and children want to wear them,” said Andrew Sedgwick, CEO of SightGlass Vision. “It’s encouraging to see eye care professionals increasingly embrace this innovation for their young patients, marking another meaningful step towards combatting the global myopia epidemic. We remain committed to bringing DOT™ lenses to children in more parts of the world.”
SightGlass Vision’s patent-protected technology has made its commercial debut in several markets, including China, the Netherlands, Israel, Canada, and Spain, as well as through preliminary market trials in other countries. † Founded in 2016, SightGlass Vision is a joint venture of CooperCompanies and EssilorLuxottica. For more information, visit SightGlassVision.com.
###
About SightGlass Vision
SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology
is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide. *This figure is based on sales data and reflects global usage across multiple regions.
†SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.
‡Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Lenses were worn 10 hours per day.
[1] Biswas S, El Kareh A, Qureshi M, Lee DMX, Sun CH, Lam JSH, Saw SM, Najjar RP. The influence of the environment and lifestyle on myopia. J Physiol Anthropol 2024;43(1):7.
[2] Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol 2023;107:1709-1715.
[3] Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. Invest. Ophthalmol. Vis. Sci. 2025;66(8):2815.
[4] McParland et al. Children adapt well to Diffusion Optics Technology™ (DOT) spectacle lenses . Presented at NCC 2024.
After 2–3 days of wearing the allocated spectacle lenses, the rate of adaptation was the same for DOT™ lenses and SV lenses (97% overall in each group).
[5] SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n=256, 14 North American sites).
